Log in
Enquire now
Neuromod

Neuromod

Neuromodulation tinnitus treatment device manufacturer.

OverviewStructured DataIssuesContributors

Contents

neuromoddevices.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Manufacturing
Manufacturing
Biotechnology
Biotechnology
Health technology
Health technology
‌
Neuromodulation (medicine)
Healthcare
Healthcare
Medical device
Medical device
Biology
Biology
Location
Dublin
Dublin
0
Forchheim
Forchheim
0
B2X
B2C
B2C
CEO
‌
Ross O'Neill
Founder
‌
Ross O'Neill
Legal Name
Neuromod Devices Ltd.
Number of Employees (Ranges)
51 – 200
Email Address
info@neuromoddevices.com0
reception@neuromodmedical.com
Phone Number
+353125314440
+35312531448
Full Address
Aeussere Nuernberger Str. 62, 91301 Forchheim, Germany0
Rainsford Street, Dublin, D08 R2YP Ireland0
Place of Incorporation
Dublin
Dublin
Investors
Panakes Partners
Panakes Partners
NDRC
NDRC
Enterprise Ireland
Enterprise Ireland
Silicon Valley Bank
Silicon Valley Bank
Fountain Healthcare Partners
Fountain Healthcare Partners
Kreos Capital
Kreos Capital
‌
Moffett Investment Holdings
Founded Date
2010
Total Funding Amount (USD)
41,084,240
Latest Funding Round Date
March 11, 2025
CFO
‌
Derek Madden
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
3
COO
‌
Diarmuid Flavin
Country
Republic of Ireland
Republic of Ireland
0
Germany
Germany
0
Headquarters
Dublin
Dublin

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
11,000,000

Neuromod is a Dublin-based company founded to develop a treatment for chronic and persistent tinnitus (ringing of the ears). It is an ISO 13485 accredited medical device manufacturer.

Lenire

Neuromod developed a medical device called Lenire that uses patented bi-modal neuromodulation to treat chronic tinnitus. Lenire is a medical device used in at-home settings for approximately 30 minutes daily to treat tinnitus symptoms. Patients utilizing this device must attend 2 follow-up appointments within a 3-month time span for device adjustments from a clinician. The adjustments made to the device are intended to optimize treatment efficacy. The Lenire device consists of three components: A controller, a tongue tip, and Bluetooth headphones. The controller is a handheld device that controls the intensity, timing, and synchronization of the sounds from headphones to the tongue stimuli. The tongue tip is responsible for providing an electronic "energy pulse," or stimuli, to the trigeminal nerve through the surface of the tip of the tongue. The Bluetooth headphones are used for customized sound that pairs to the tongue stimuli. The headphones are trademarked by Harman International, a subsidiary of Samsung Electronics.

Case Study

Lenire was tested in a clinical trial at St. James Hospital in Dublin, Ireland, and Tinnituszentrum of the University Regensburg, Germany, between 2016 and 2019. The study was conducted with 326 participants over a 12-month period with a data collection point conducted in month 3. The study findings reported that approximately 86% of treatment-compliant patients experienced symptom improvement after 12 weeks of treatment. Additionally, the study showed that Lenire provided symptom relief in approximately 80% of treatment-compliant patients after a 12-month period.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Neuromod

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.